Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Nov 15;19(22):6064-6.
doi: 10.1158/1078-0432.CCR-13-2461. Epub 2013 Oct 4.

Test-firing ammunition for spliceosome inhibition in cancer

Scott M Dehm  1
Affiliations
Comment

Test-firing ammunition for spliceosome inhibition in cancer

Scott M Dehm. Clin Cancer Res. .

Abstract

E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy. Clin Cancer Res; 19(22); 6064-6. ©2013 AACR.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: none

Figures

Fig. 1
Fig. 1
Mechanism-of-action schematic for E7107 and spliceosome inhibitors. E7107 inhibits splicing by blocking association of U2 snRNP with the intron branch point in pre-mRNAs. E7107 and spliceosome inhibitors bind SF3b complex core components SAP155, SA145, and SAP130.
See this image and copyright information in PMC

Comment on

References

    1. Eskens FA, Ramos FJ, Burger H, O’Brien JP, Piera A, de Jonge MJ, et al. Phase I, Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2013 - PubMed
    1. Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E, Munoz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 2013;14:153–65. - PubMed
    1. Golas MM, Sander B, Will CL, Luhrmann R, Stark H. Molecular architecture of the multiprotein splicing factor SF3b. Science. 2003;300:980–4. - PubMed
    1. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007;8:749–61. - PubMed
    1. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010;24:2343–64. - PMC - PubMed

LinkOut - more resources